Background and objective: The objective of this study is the presentation of results obtained in the abstinence rate and relapse of the smoking practice after a 12-month pharmacotherapeutic follow-up in a pharmacy office. Subjects and methods: Smokers assigned referred to the pharmacy for a pharmacotherapeutic follow-up with varenicline treatment. Abstinence and relapses were evaluated at 5, 12 and 52 weeks. The abstinence obtained was by self-declaration verifying it with coxymetry of 6 ppm or less. Results: 78 patients (53.8% males), 43.92 (± 9.41) years and 27.36 (± 10.54) years of mean duration. 71.8% patients treated varenicline therapy and 28.2% were not treated with a drug. Of the 56 patients treated, completed 12 weeks of treatment 21.4%. 50% of subjects remained non-smoking at 12-week treatment and at the end of follow-up at 52 weeks only 33.9% remained abstinent. Conclusion: There were high rates of relapse per year, which depended on adherence. Patients who had more adherence to treatment had better annual abstinence rates.